Archivos en Investigación del Cáncer

  • ISSN: 2254-6081
  • Índice h de la revista: 13
  • Puntuación de cita de revista: 3.58
  • Factor de impacto de la revista: 3.12
Indexado en
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • CiteFactor
  • OCLC-WorldCat
  • Publón
  • Fundación de Ginebra para la Educación e Investigación Médica
  • Google Académico
  • Laboratorios secretos de motores de búsqueda
Comparte esta página

Abstracto

Lymphoma: Understanding the Complexities of Blood Cancer

Jennifer Fernandez

Lymphoma is a diverse group of blood cancers that originate from abnormal growth in the lymphatic system's lymphocytes, crucial cells of the immune system. It can be broadly classified into Hodgkin lymphoma and non-Hodgkin lymphoma (NHL), each encompassing various subtypes with unique characteristics and treatment approaches. The exact causes of lymphoma remains unclear, but certain risk factors, such as immune system disorders, viral infections, age, gender, and family history, are associated with increased susceptibility. Diagnosing lymphoma involves physical examination, blood tests, imaging studies, and lymph node biopsy. Treatment options depend on the type, stage, and individual factors, including chemotherapy, radiation therapy, immunotherapy, targeted therapy, and stem cell transplant. Advancements in research have led to improved treatments and outcomes for lymphoma patients, with ongoing clinical trials exploring innovative therapies. Early detection, accurate diagnosis, and timely intervention play a crucial role in enhancing patient outcomes. Public awareness, supports for research, and early screening efforts are essential in the fight against this complex group of blood cancers. Collaborative efforts from the medical community and the public can lead to better treatments and improved quality of life for individuals affected by lymphoma.

Keywords

Lymphoma; Blood cancers; Abnormal growth; Immunotherapy

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado